NEW YORK, NY / ACCESSWIRE / August 27, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Eagle Bancorp, Inc. (NASDAQGS:EGBN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/eagle-bancorp-inc-loss-submission-form?prid=3213&wire=1
Lead Plaintiff Deadline: September 23, 2019
Class Period: March 2, 2015 to July 17, 2019
Allegations against EGBN include that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Curaleaf Holdings, Inc. (OTCMKTS:CURLF)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/curaleaf-holdings-inc-loss-submission-form?prid=3213&wire=1
Lead Plaintiff Deadline: October 4, 2019
Class Period: November 21, 2018 to July 22, 2019
Allegations against CURLF include that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Abiomed, Inc. (NASDAQGS:ABMD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/abiomed-inc-loss-submission-form?prid=3213&wire=1
Lead Plaintiff Deadline: October 7, 2019
Class Period: January 31, 2019 to July 31, 2019
Allegations against ABMD include that: (i) Abiomed’s revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong